Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

今朝の抄読会より。Soliomab、上皮性卵巣癌の表面抗原とCD3の両方に結合（bispecific antibody BiTEというらしい）して腫瘍へのT細胞免疫を誘導。IgGの可変部位を２つ取り出して繋げた様なもの？面白い＞ http://t.co/uK4CjOJQon

Solitomab represents a promising agent for treatment of chemo-resistant ovarian cancers that overexpress EpCAM. http://t.co/TAfqHZ1y5A